Log In
person
Castle Biosciences Inc
CSTL
summarize
3 total product lines
calendar_month
Revenue as of 12/31/2023
| Reporting Segmentarrow_drop_up | Product Line | Amount (USD) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (USD) | Percentage |
| Skin Cancer Pharma |
Genetic, Genomic, and Sequencing Medical Diagnostic Services; Government Insurance
These companies operate genetic diagnostic labs. Medical service professionals order diagnostic tests for patients, but the diagnostic services firms bill either the patient directly or through the patient''s insurance provider. The majority of revenue is ultimately derived from government insurance payer programs.
|
107.7M | 49.00% |
| Skin Cancer Pharma |
Genetic, Genomic, and Sequencing Medical Diagnostic Services; Diversified Payors
These companies operate Genetic, Genomic, and Sequencing diagnostic labs. Medical service professionals order diagnostic tests for patients, but the diagnostic services firms bill either the patient directly or through the patient''s insurance provider. Revenue is ultimately derived from commercial insurance providers, consumers as well as medicare and medicaid.
|
81.32M | 37.00% |
| Skin Cancer Pharma |
Genetic, Genomic, and Sequencing Medical Diagnostic Services; Private Insurance
These companies operate genetic diagnostic labs. Medical service professionals order diagnostic tests for patients, but the diagnostic services firms bill either the patient directly or through the patient''s insurance provider. The majority of revenue is ultimately derived from commercial insurance providers.
|
30.77M | 14.00% |
| keyboard_arrow_down |
Skin Cancer Pharma
Genetic, Genomic, and Sequencing Medical Diagnostic Services; Government Insurance
|
107.7M | 49.00% |
| keyboard_arrow_right |
These companies operate genetic diagnostic labs. Medical service professionals order diagnostic tests for patients, but the diagnostic services firms bill either the patient directly or through the patient''s insurance provider. The majority of revenue is ultimately derived from government insurance payer programs.
|
||
| keyboard_arrow_down |
Skin Cancer Pharma
Genetic, Genomic, and Sequencing Medical Diagnostic Services; Diversified Payors
|
81.32M | 37.00% |
| keyboard_arrow_right |
These companies operate Genetic, Genomic, and Sequencing diagnostic labs. Medical service professionals order diagnostic tests for patients, but the diagnostic services firms bill either the patient directly or through the patient''s insurance provider. Revenue is ultimately derived from commercial insurance providers, consumers as well as medicare and medicaid.
|
||
| keyboard_arrow_down |
Skin Cancer Pharma
Genetic, Genomic, and Sequencing Medical Diagnostic Services; Private Insurance
|
30.77M | 14.00% |
| keyboard_arrow_right |
These companies operate genetic diagnostic labs. Medical service professionals order diagnostic tests for patients, but the diagnostic services firms bill either the patient directly or through the patient''s insurance provider. The majority of revenue is ultimately derived from commercial insurance providers.
|
||